Literature DB >> 17960326

Pharmacophore modeling and parallel screening for PPAR ligands.

Patrick Markt1, Daniela Schuster, Johannes Kirchmair, Christian Laggner, Thierry Langer.   

Abstract

We describe the generation and validation of pharmacophore models for PPARs, as well as a large scale validation of the parallel screening approach by screening PPAR ligands against a large database of structure-based models. A large test set of 357 PPAR ligands was screened against 48 PPAR models to determine the best models for agonists of PPAR-alpha, PPAR-delta, and PPAR-gamma. Afterwards, a parallel screen was performed using the 357 PPAR ligands and 47 structure-based models for PPARs, which were integrated into a 1537 models comprising in-house pharmacophore database, to assess the enrichment of PPAR ligands within the PPAR hypotheses. For these purposes, we categorized the 1537 database models into 181 protein targets and developed a score that ranks the retrieved targets for each ligand. Thus, we tried to find out if the concept of parallel screening is able to predict the correct pharmacological target for a set of compounds. The PPAR target was ranked first more often than any other target. This confirms the ability of parallel screening to forecast the pharmacological active target for a set of compounds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17960326     DOI: 10.1007/s10822-007-9140-0

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  39 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

Review 2.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

3.  LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters.

Authors:  Gerhard Wolber; Thierry Langer
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

4.  Design and synthesis of potent and subtype-selective PPARalpha agonists.

Authors:  Ranjit C Desai; Edward Metzger; Conrad Santini; Peter T Meinke; James V Heck; Joel P Berger; Karen L MacNaul; Tian-quan Cai; Samuel D Wright; Arun Agrawal; David E Moller; Soumya P Sahoo
Journal:  Bioorg Med Chem Lett       Date:  2005-12-27       Impact factor: 2.823

5.  Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.

Authors:  Neeraj Mahindroo; Chiung-Chiu Wang; Chun-Chen Liao; Chien-Fu Huang; I-Lin Lu; Tzu-Wen Lien; Yi-Huei Peng; Wei-Jan Huang; Ying-Ting Lin; Ming-Chen Hsu; Chia-Hui Lin; Chia-Hua Tsai; John T-A Hsu; Xin Chen; Ping-Chiang Lyu; Yu-Sheng Chao; Su-Ying Wu; Hsing-Pang Hsieh
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

6.  Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.

Authors:  Weibke Arlt; Partha Neogi; Coleman Gross; Walter L Miller
Journal:  J Mol Endocrinol       Date:  2004-04       Impact factor: 5.098

7.  Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening.

Authors:  Theodora Steindl; Thierry Langer
Journal:  J Chem Inf Comput Sci       Date:  2004 Sep-Oct

8.  PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect.

Authors:  Alexandre Trifilieff; Anne Bench; Marcus Hanley; Debbie Bayley; Emma Campbell; Paul Whittaker
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.

Authors:  Zhibin Li; Chenzhong Liao; Ben C B Ko; Song Shan; Edith H Y Tong; Zihui Yin; Desi Pan; Vincent K W Wong; Leming Shi; Zhi-Qiang Ning; Weiming Hu; Jiaju Zhou; Stephen S M Chung; Xian-Ping Lu
Journal:  Bioorg Med Chem Lett       Date:  2004-07-05       Impact factor: 2.823

10.  Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model.

Authors:  Philip J Rybczynski; Roxanne E Zeck; Joseph Dudash; Donald W Combs; Thomas P Burris; Maria Yang; Melville C Osborne; Xiaoli Chen; Keith T Demarest
Journal:  J Med Chem       Date:  2004-01-01       Impact factor: 7.446

View more
  15 in total

1.  Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity.

Authors:  Kenji Chamoto; Partha S Chowdhury; Alok Kumar; Kazuhiro Sonomura; Fumihiko Matsuda; Sidonia Fagarasan; Tasuku Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

2.  Pharmacophore-driven identification of PPARγ agonists from natural sources.

Authors:  Rasmus K Petersen; Kathrine B Christensen; Andreana N Assimopoulou; Xavier Fretté; Vassilios P Papageorgiou; Karsten Kristiansen; Irene Kouskoumvekaki
Journal:  J Comput Aided Mol Des       Date:  2010-11-11       Impact factor: 3.686

3.  Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands.

Authors:  Stephanie N Lewis; Zulma Garcia; Raquel Hontecillas; Josep Bassaganya-Riera; David R Bevan
Journal:  J Comput Aided Mol Des       Date:  2015-01-24       Impact factor: 3.686

4.  Discovery of peroxisome proliferator-activated receptor α (PPARα) activators with a ligand-screening system using a human PPARα-expressing cell line.

Authors:  Keisuke Tachibana; Tomohiro Yuzuriha; Ryotaro Tabata; Syohei Fukuda; Takashi Maegawa; Rika Takahashi; Keiichi Tanimoto; Hirofumi Tsujino; Kazuto Nunomura; Bangzhong Lin; Yoshiharu Matsuura; Toshiya Tanaka; Takao Hamakubo; Juro Sakai; Tatsuhiko Kodama; Tadayuki Kobayashi; Kenji Ishimoto; Hiroyuki Miyachi; Takefumi Doi
Journal:  J Biol Chem       Date:  2018-05-15       Impact factor: 5.157

5.  Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma.

Authors:  Nanang Fakhrudin; Angela Ladurner; Atanas G Atanasov; Elke H Heiss; Lisa Baumgartner; Patrick Markt; Daniela Schuster; Ernst P Ellmerer; Gerhard Wolber; Judith M Rollinger; Hermann Stuppner; Verena M Dirsch
Journal:  Mol Pharmacol       Date:  2010-01-11       Impact factor: 4.436

Review 6.  Accessing biological actions of Ganoderma secondary metabolites by in silico profiling.

Authors:  Ulrike Grienke; Teresa Kaserer; Florian Pfluger; Christina E Mair; Thierry Langer; Daniela Schuster; Judith M Rollinger
Journal:  Phytochemistry       Date:  2014-11-06       Impact factor: 4.072

7.  Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding.

Authors:  Fernanda A H Batista; Daniela B B Trivella; Amanda Bernardes; Joyce Gratieri; Paulo S L Oliveira; Ana Carolina M Figueira; Paul Webb; Igor Polikarpov
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.752

8.  Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ.

Authors:  Stephanie N Lewis; Lera Brannan; Amir J Guri; Pinyi Lu; Raquel Hontecillas; Josep Bassaganya-Riera; David R Bevan
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

9.  Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.

Authors:  Ying Ma; Shu-Qing Wang; Wei-Ren Xu; Run-Ling Wang; Kuo-Chen Chou
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

10.  Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics.

Authors:  Lei Liu; Ying Ma; Run-Ling Wang; Wei-Ren Xu; Shu-Qing Wang; Kuo-Chen Chou
Journal:  Drug Des Devel Ther       Date:  2013-04-08       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.